一名转移性前列腺癌患者对促性腺激素释放激素激动剂产生耐药性。 - Suppr | 超能文献

Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.

作者信息

Krongrad A, Brady J, Rodriguez R J

出版信息

South Med J. 1997 Apr;90(4):460-1. doi: 10.1097/00007611-199704000-00025.

DOI:10.1097/00007611-199704000-00025

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.一名转移性前列腺癌患者对促性腺激素释放激素激动剂产生耐药性。

South Med J. 1997 Apr;90(4):460-1. doi: 10.1097/00007611-199704000-00025.

2

Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?促性腺激素释放激素激动剂在注射部位有无无菌性脓肿形成时的失效情况：对机制的深入了解？

Urology. 2006 May;67(5):1084.e15-7. doi: 10.1016/j.urology.2005.11.015.

3

Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy.

S Afr Med J. 2006 Sep;96(9):810-1.

4

[Diferelin treatment of primary local and generalized cancer of the prostate].

Urologiia. 2001 Nov-Dec(6):17-9.

5

Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.双膦酸盐疗法用于治疗伴有骨转移的激素难治性前列腺癌。

J Urol. 2003 Jan;169(1):281-2. doi: 10.1016/S0022-5347(05)64093-1.

6

Treatment of an orchiectomized patient with hormone-refractory prostate cancer with LH-RH agonists.用促性腺激素释放激素（LH-RH）激动剂治疗去势的激素难治性前列腺癌患者。

Eur Urol. 2001 Oct;40(4):474-6; discussion 477. doi: 10.1159/000049819.

7

Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.在一名前列腺癌患者的促黄体生成素释放激素激动剂治疗期间，未能维持血清睾酮的抑制水平。

Int J Urol. 2002 Jun;9(6):359-61. doi: 10.1046/j.1442-2042.2002.00476.x.

8

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.针对雄激素非依赖性前列腺癌的促卵泡激素（FSH）：阿巴瑞克用于睾丸切除术后进展的前列腺癌

Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045.

9

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.多西他赛、磷酸雌莫司汀和唑来膦酸联合治疗雄激素非依赖性转移性前列腺癌：疗效、安全性及临床获益评估

Urology. 2005 Jan;65(1):126-30. doi: 10.1016/j.urology.2004.08.041.

10

High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.一名转移性前列腺癌患者血清总前列腺特异性抗原和游离前列腺特异性抗原中的高剂量钩状效应

J Urol. 2001 Jul;166(1):213.

引用本文的文献

1

Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.在接受黄体生成素释放激素激动剂治疗的前列腺癌患者中，未能达到去势水平的血清睾酮。

Anticancer Drugs. 2020 Nov;31(10):1099-1102. doi: 10.1097/CAD.0000000000000986.

2

Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration.对于激素难治性转移性前列腺癌患者，手术去势可作为药物去势的一种替代方法。

Adv Urol. 2012;2012:979154. doi: 10.1155/2012/979154. Epub 2011 Jun 15.